Abstract: A method and a system are disclosed for determining application dependency paths in a data center. The method and the system captures application traffic volume data on the servers with switches and monitoring agents; generates an application traffic matrix of all the components of the applications based on the application traffic volume data; estimates the number of the applications in the data center from the traffic matrix with a Rank Estimation via Singular Value Decomposition or Power Factorization Residue Errors process; and decomposes the traffic matrix into a first matrix and a second matrix with a non-negative matrix factorization process using the estimated number of applications. The first matrix represents a set of the components belonging to each of the applications and the second matrix represents the amount of traffic generated by each application over time. Any noise in the first and second matrices is removed with a concurrent volumes ratios based correlation process.

Abstract: A method and an apparatus for driving multi-segment display device are described. According to the present invention, problems of driving the electrode wire activation mode of the conventional liquid crystal display are solved by the driving waveforms. The driving waveforms of non-display area are in the OFF mode, where the non-display area has pixels in the OFF mode, driving electrode wires and background area. Problems of driving voltage wire activation mode are decreased, cost is lowered, and processing is simplified, so that every pixel of the display device will be controlled precisely.

Abstract: The present disclosure is generally directed to compounds that can inhibit DAGL? and/or ? activity, compositions comprising such compounds, and methods for inhibiting DAGL? and/or ? activity.

Abstract: The present disclosure is generally directed to compounds that can inhibit DAGL? and/or ? activity, compositions comprising such compounds, and methods for inhibiting DAGL? and/or ? activity.

Abstract: An antenna module that includes two directional antennae arranged in a back-to-back manner, and a converter. The converter realizes conversion between an omnidirectional antenna mode and a directional antenna mode by switching on two directional antennae simultaneously or by switching on one of the directional antennas. Alternatively, the antenna module includes a horizontal polarization antenna, a vertical polarization antenna and a converter, where the converter provides the conversion between the horizontal polarization antenna mode and the vertical polarization antenna mode by switching on the horizontal polarization antenna or the vertical polarization antenna.

Abstract: A semitransparent photovoltaic film is provided, including a flexible substrate that integrates a plurality of first and second planar portions, and a plurality of photovoltaic cells. An angle is also included correspondingly between the first and the second planar portions. The photovoltaic cells are formed on a plurality of surfaces of the first planar portions of the flexible substrate. According to a design of the semitransparent photovoltaic film, most directly incident sunlight is absorbed and then converted into electricity, and most of the lights progressing horizontally or on a upward slant can pass through the film, thereby achieving the transparent visual effect.

Abstract: A package device has a package substrate, a semiconductor die on the package substrate, and a molding compound on the package substrate and over the semiconductor die. The semiconductor die has a last passivation layer, an active circuit region in an internal portion of the die, an edge seal region along a periphery of the die, and a structure over the edge seal region extending above the last passivation layer, covered by the molding compound, and comprising a polymer material. The structure may extend at least five microns above the last passivation layer. The structure stops cracks in the molding compound from reaching the active circuit region. The cracks, if not stopped, can reach wire bonds in the active region and cause them to fail.

Abstract: A composition having clevidipine as an active ingredient is described. The composition includes clevidipine as an active ingredient and an amount of the impurity H168/79 that is no greater than about 1.5%, or where the ratio between clevidipine and H168/79 is equal or above 60 to 1.

Abstract: Pharmaceutical compositions, and a method of stabilizing pharmaceutical compositions having clevidipine, or any pharmaceutically acceptable salt thereof, as the active ingredient is described. The method includes the slowing down or inhibiting of the oxidation pathway of clevidipine. This can be accomplished by reducing the amount the pharmaceutical composition is exposed to oxygen and/or light during the manufacturing and storing processes. According to this method, oxygen must be removed or replaced, or light must be sufficiently blocked such that light energy cannot reach the active ingredient of the composition, or is reduced to a level that the light-induced oxidation reaction converting clevidipine to H324/78 is minimized, such that the total detectable level of H324/78 in a given composition sample does not exceed about 0.2% on a weight-by-weight basis, or the ratio of clevidipine to H324/78 is equal to or greater than about 450 to 1 on a weight-to-weight basis.

Abstract: The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract: A package device has a package substrate, a semiconductor die on the package substrate, and a molding compound on the package substrate and over the semiconductor die. The semiconductor die has a last passivation layer, an active circuit region in an internal portion of the die, an edge seal region along a periphery of the die, and a structure over the edge seal region extending above the last passivation layer, covered by the molding compound, and comprising a polymer material. The structure may extend at least five microns above the last passivation layer. The structure stops cracks in the molding compound from reaching the active circuit region. The cracks, if not stopped, can reach wire bonds in the active region and cause them to fail.

Abstract: The invention is directed to a method for forming a flexible electro-optic film. The method comprises steps of providing a first substrate having a conductive layer formed thereon and then forming a first locating structure over the conductive layer, wherein the locating structure includes target regions and periphery regions. The surface tension of the target regions is difference from that of the periphery regions. Thereafter, an electro-optic medium placing process for forming an electro-optic droplet on each of the target regions is performed. A solidifying process for forming a capsule wall covering the electro-optic droplet on each of the target regions is performed. The first substrate is laminated with a second substrate.

Abstract: A modulized display component and a manufacturing method for the same are disclosed in this invention. The display component of this invention is designed according to a modulization concept so that it can be attached to any driving circuit layer. Further, various manufacturing techniques can be used to form the alignment layers and protective layers in order to fabricate a trans-reflective, reflective, or transmissive color displaying component.

Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Abstract: A modulized display component and a manufacturing method for the same are disclosed in this invention. The display component of this invention is designed according to a modulization concept so that it can be attached to any driving circuit layer. Further, various manufacturing techniques can be used to form the alignment layers and protective layers in order to fabricate a trans-reflective, reflective, or transmissive color displaying component.

Abstract: The present disclosure relates to tripeptide compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Abstract: A display-enabled electronic system. The display-card electronic comprises an external device and card-type device receiving the external device. The external device provides a data signal. The card-type device comprises a card body, at least one image display unit, and an interface. The card body comprises a display surface and a receiving portion. The image display unit disposed in the display surface displays corresponding images in response to the data signal. The interface disposed in the receiving portion, electrically connects to the external device to transmit the data signal.

Abstract: A method of manufacturing a display panel and a display panel are described. A first substrate is provided. A wall structure is formed on the first substrate to define several microcups. A displaying medium is filled into the microcups. Thereafter, a sealing material is formed over the microcups filled with the displaying medium. A second substrate is put over the sealing material and a lamination process is performed, wherein the sealing material which contacts the wall structure bonds the second substrate to the wall structure, and the sealing material which contacts the displaying medium dissolves in the displaying medium.

Abstract: The invention encompasses compounds of formula I as well as compositions and methods of using the compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.

Abstract: The invention encompasses compounds of formula I, including pharmaceutically acceptable salts, as well as compositions and methods of using these compounds. The compounds have activity against hepatitis C virus (HCV) and are useful in treating those infected with HCV.